Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Gene Therapy CRO Services
At Cyagen, we streamline your gene therapy pipeline—from AI-driven target discovery and AAV vector design to disease model generation and in vivo efficacy testing. Our integrated platform empowers translational research with speed, precision, and scientific confidence.
Visualize Your Path to Gene Therapy Success
Navigate every stage of your gene therapy program with clarity and confidence. Our integrated workflow guides you from target discovery through vector engineering, model generation, and efficacy validation—ensuring scientific continuity at every step.
{{ item.title }}
{{static_tabs[0].title}}
Predict. Validate. Accelerate.
AI-enabled discovery of therapeutic targets and pathogenic mutations.
Cyagen integrates advanced AI modeling with our proprietary rare disease database (RDDC) to predict pathogenic gene mutations, design relevant models, and validate therapeutic targets. Our platform bridges bioinformatics and wet-lab validation to de-risk and fast-track gene therapy pipelines.
AI-Based Variant Prediction
Predict high-risk pathogenic variants using deep learning.
Model-Based Target Validation
Validate targets via custom cellular and animal models.
Rare Disease Data Center (RDDC)
Access curated mutation-disease databases for therapy design.
Integrated Screening Tools
Visualize mutation effects and explore RNA splicing outcomes.
AI-Based Variant Prediction
Uncover Disease-Causing Mutations with Predictive Precision
Evaluate the pathogenic potential and splicing consequences of genetic variants using our AI-powered tools – Pathogenicity Predictor and RNA Splicer. These tools leverage curated datasets from diseases like Duchenne Muscular Dystrophy (DMD) to identify fun
Figure 1. Visualization from Cyagen’s RNA Splicer tool showing splicing impact prediction of a pathogenic DMD variant.
Model-Based Target Validation
Validate Functional Impact Using Custom Cell and Animal Models
Translate predicted targets into experimental systems. Cyagen offers KO, KI, and overexpression models—available in both rodent and cellular platforms—to confirm variant pathogenicity and assess gene therapy responsiveness in vivo and in vitro.
Rare Disease Data Center (RDDC)
A Curated AI-Ready Database for Rare Disease Research
RDDC is a centralized hub for rare disease discovery, integrating gene-disease associations, variant annotation, epidemiological data, and model repositories. Researchers can identify targetable mutations and associated models for over 3,000 rare conditions—all with AI-powered filters.
→ Access RDDC Database
Integrated Screening Tools
Visualize Genotype-Phenotype Linkages in Seconds
Interact with gene, mutation, and model data via our visual dashboards and natural language tools. From variant prioritization to model recommendation, our screening platform simplifies early-stage decision-making for gene therapy programs.
{{static_tabs[1].title}}
Design. Deliver. Transform.
AI-enhanced AAV vector engineering, high-titer packaging, and in vivo validation—all in one place.
Cyagen’s AAV service platform supports the full cycle of vector development—from AI-optimized capsid selection and cloning to customized packaging, purification, and QC validation. Our inventory includes both off-the-shelf AAV serotypes and proprietary capsid variants for brain, eye, and systemic delivery. Backed by validated in vivo and in vitro data, we ensure reliable performance in your gene therapy research.
AI-Assisted AAV Capsid Design
Customize AAV serotype and cassette for your target tissue.
High-Titer AAV Production
Scalable production of high-quality AAVs with rigorous titering and purity validation.
Ready-to-Ship AAVs
Access validated AAVs for common gene therapy applications – shipped globally.
In Vitro & In Vivo Validation
Ensure precise delivery into target tissues with expert-guided stereotaxic or systemic injection.
AI-Assisted AAV Capsid Design
Customize Capsids for Precise Targeting and Tissue Penetration
Leverage our AI-trained models to design capsids with enhanced targeting for CNS, ocular, or hepatic delivery. Our proprietary variants (e.g., PM167, PM170) demonstrate superior infectivity and organ selectivity—validated by in vivo data in C57BL/6J mice.
Figure 2. In vivo fluorescence imaging showing enhanced CNS tropism of PM167 and PM170 compared to PHP.eB.
→ View Capsid Variants
High-Titer AAV Production Services
Customize Capsids for Precise Targeting and Tissue Penetration
Using triple transfection and advanced purification protocols, Cyagen provides high-purity, high-titer AAVs with customizable serotypes and payloads. Our QC ensures >95% purity and endotoxin <10 EU/ml—delivered in as fast as 2 weeks.
Figure 3. Fluorescence microscopy showing high infection efficiency in 293T cells by AAV2-GFP at different MOIs.
Ready-to-Ship AAVs
Validated AAV Serotypes and AI-Optimized Variants
Access off-the-shelf AAV products for immediate research needs. Cyagen offers standard serotypes and proprietary variants (e.g., PM077, PM021, PM054) with validated expression in CNS and ocular tissues. Each lot is quality-controlled and pre-tested for infectivity.
Figure 4. Comparative analysis of retinal layer penetration by AAV2-WT vs. PM021 and PM054. PM054 shows 10x improved retinal penetration.
→ Browse AAV Stock Library
In Vitro & In Vivo Validation
Verify Expression Before Preclinical Evaluation
We test vector efficiency across tissues using fluorescence, qPCR, and functional phenotyping. AAV variants like PM077 and PM054 show enhanced ocular penetration, validated via retinal layer imaging post-injection.
Figure 5. Frozen section of mouse eye tissue shows superior retinal transduction by PM054 compared to AAV2-WT.
{{static_tabs[2].title}}
Build. Validate. Translate.
Custom cellular and animal models for functional validation of gene therapy targets.
Cyagen’s model generation platform empowers researchers to evaluate therapeutic candidates in biologically relevant systems—from in vitro transduction assays to disease-representative rodent models. We offer precise genome engineering for KO, KI, and overexpression models, paired with comprehensive histological and biomarker validation to ensure translational relevance for preclinical studies.
In Vitro Functional Assays
Validate gene function and transduction efficiency in cellular systems.
Rodent Model Generation
Create disease-relevant KO, KI, and overexpression models for preclinical research.
Histology & Biomarker Analysis
Confirm tissue-level changes and biomarker profiles with precision.
In Vitro Functional Assays
Test Transgene Effects in a Controlled Cellular Environment
Use our optimized cell-based platforms to evaluate AAV-mediated transduction efficiency, protein expression, and cell viability. Ideal for early-stage screening before in vivo validation.
Rodent Model Generation
Validate Gene Function and Therapeutic Potential In Vivo
Establish knockout, knockin, or overexpression mouse models tailored to your gene of interest. Available on immunodeficient, humanized, or tissue-specific backgrounds.
→ Explore Rodent Model Library
Histology & Biomarker Analysis
Uncover Biological Impact at the Tissue and Molecular Level
Perform detailed pathological analysis, including H&E, IHC/IF, and biomarker profiling (e.g., dystrophin, inflammation, fibrosis markers) to confirm therapeutic response.
{{static_tabs[3].title}}
Deliver with Precision. Validate with Confidence.
Expert-guided CNS drug delivery to support gene therapy research.
Cyagen’s preclinical pharmacology team offers in vivo drug delivery services tailored for CNS-targeted gene therapy research. From stereotactic injections into precise brain regions to systemic administration methods, our experts ensure accuracy and reproducibility through standardized procedures and post-delivery validation. Backed by imaging and biomarker readouts, we help researchers confirm delivery success and downstream therapeutic effects.
Stereotactic Brain Injection
High-precision delivery to defined brain regions using 3D coordinate systems.
Intrathecal Injection
Direct administration into cerebrospinal fluid (CSF) via lumbar puncture or cisterna magna.
Intravenous (IV) Injection
Systemic delivery allowing broader biodistribution and tissue transduction.
Additional Routes
Intramuscular, subcutaneous, intranasal, intraperitoneal, and more – based on research goals.
Case Highlight
Example 1 – Precise Brain Targeting via Stereotactic Injection
  • Substance: AAV5-CAG-EGFP, AAV9-CAG-EGFP, PM227-CAG-EGFP
  • Method: Stereotactic injection
  • Target Site: Bilateral striatum
  • Validation: EGFP expression observed 4 weeks post-injection via native fluorescence imaging, confirming successful localized brain transduction.
Figure 6. Representative coronal brain sections from mice stereotactically injected with AAV5, AAV9, or PM227 vectors targeting the striatum. EGFP signal (green) shows transgene expression; DAPI (blue) labels nuclei. Merge images highlight co-localization. Brain atlas reference indicates targeting region.
Example 2 – Systemic Administration for Brain-Wide Gene Delivery
  • Substance: AAV9, AAV-PHP.eB, PM228
  • Method: Intravenous injection via tail vein
  • Validation: Robust, brain-wide GFP signal detected via immunofluorescence 3 weeks after administration, confirming efficient transduction across brain tissues.
Figure 7. Sagittal brain sections showing widespread EGFP expression following intravenous delivery of AAV9 WT, PHP.eB, and PM228 vectors. Green: EGFP signal; Blue: DAPI-stained nuclei. Merge panels show broad transgene distribution throughout brain parenchyma.
{{static_tabs[4].title}}
Measure. Analyze. Optimize.
Multi-tiered in vivo and in vitro assessments to quantify therapeutic efficacy.
Cyagen delivers a full suite of efficacy evaluation services to support gene therapy development. Whether assessing vector performance, biomarker expression, immune response, or behavioral outcomes, our platform ensures scientific rigor and translational relevance. Testing is conducted in validated models using standardized assays across molecular, cellular, tissue, and systemic levels.
Molecular & Cellular Assays
qPCR, western blot, ELISA, and IF to quantify transgene expression and protein function.
Functional Cell Readouts
Assays for proliferation, apoptosis, migration, and cellular response to therapy.
Behavioral Studies
Water maze, open field, and gait analysis to evaluate CNS recovery or degeneration.
Ocular Phenotyping
Retinal flat mount, ERG, and fundus imaging for evaluating ocular gene therapy.
Case Highlight
Example – ASO-Mediated SMN Restoration in SMA Model
  • Model: B6-hSMN2 mouse
  • Assay: Western blot and IHC (ChAT staining)
  • Outcome: ASO-10-27 treatment led to increased SMN protein levels and significantly higher numbers of spinal motor neurons, indicating effective target engagement and phenotypic improvement in the SMA model.
Figure 8. Western blot analyses confirm increased SMN protein levels in B6-hSMN2 mice after ASO-10-27 administration, indicating successful gene regulation. Immunohistochemistry (ChAT staining) further shows an increased number of spinal motor neurons following treatment.
Our Unique Advantages
One Partner, Full Pipeline
Streamline your entire gene therapy workflow—target discovery, AAV design, model generation, and validation—all in one place.
AI-Powered Discovery
Accelerate progress with AI-guided variant prediction, splicing analysis, and capsid optimization from our proprietary RDDC platform.
Human-Relevant Models
Access validated humanized and disease-specific models, including HUGO-GT™ mice tailored for gene therapy research.
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Inquiry Details
Main Area of Research
Service(s) of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest